If we obtain approval to commercialize any products outside of the U.S.; a variety of risks associated with international operations could materially adversely affect our business. If our product candidates are approved for commercialization; we intend to enter into agreements with third parties to market those product candidates outside the U.S.; including for arhalofenate and MBX 8025. We expect that we will be subject to additional risks related to international operations; including the following different regulatory requirements for drug approvals in foreign countries reduced protection for intellectual property rights unexpected changes in tariffs; trade barriers and regulatory requirements economic weakness; including inflation; or political instability in particular foreign economies and markets compliance with tax; employment; immigration and labor laws for employees living or traveling abroad foreign taxes; including withholding of payroll taxes foreign currency fluctuations; which could result in increased operating expenses and reduced revenues; and other obligations incident to doing business in another country workforce uncertainty in countries where labor unrest is more common than in the U.S. production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad and business interruptions resulting from geopolitical actions; including war and terrorism; pandemics; or natural disasters including earthquakes; typhoons; volcanic eruptions; floods and fires. We have no prior experience in these areas. In addition; there are complex regulatory; tax; labor and other legal requirements imposed by both the European Union and many of the individual countries in Europe with which we will need to comply. Many U.S. based biopharmaceutical companies have found the process of marketing their own products in Europe to be very challenging. 48 Table of Contents Index to Financial Statements